Results 51 to 60 of about 32,363 (292)

Glucose-Induced Hemodynamic and Metabolic Response of Skeletal Muscle in Heart Failure Patients with Reduced vs. Preserved Ejection Fraction—A Pilot Study

Journal of Cardiovascular Development and Disease, 2022
(1) Background: Insulin resistance (IR) is a characteristic pathophysiologic feature in heart failure (HF). We tested the hypothesis that skeletal muscle metabolism is differently impaired in patients with reduced (HFrEF) vs.
Michael Boschmann, Lars Klug, Frank Edelmann, Anja Sandek, Stephan von Haehling, Hans-Dirk Düngen, Jochen Springer, Stefan D. Anker, Wolfram Doehner, Nadja Jauert   +9 more
doaj   +1 more source

Effect of selective heart rate slowing in heart failure with preserved ejection fraction [PDF]

, 2015
Background Heart failure with preserved ejection fraction (HFpEF) is associated with significant morbidity and mortality but is currently refractory to therapy.
Ashrafian, Houman, Dawson, Dana K., Dwight, Jeremy S., Francis, Jane M., Frenneaux, Michael, Mahmod, Masliza, Neubauer, Stefan, Pal, Nikhil, Rudd, Amelia, Singh, Satnam, Sivaswamy, Nadiya, Watkins, Hugh, Yavari, Arash   +12 more
core   +2 more sources

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

VDD-ICD Implantation in a Patient with Dextrocardia and Corrected Transposition of the Great Arteries

Cardiologia Hungarica
We present the case of a 52-year-old female patient on optimal medical therapy (OMT) for heart failure with severely reduced ejection fraction. She was diagnosed with dextrocardia and congenital corrected transposition of the great arteries (ccTGA) by ...
Krisztián István Kássa, Zoltán Som, Attila Kardos, Csaba Földesi   +3 more
doaj   +1 more source

The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence

Therapeutics and Clinical Risk Management, 2021
Manasvi Gupta,1 Shiavax Rao,2 Gaurav Manek,1 Gregg C Fonarow,3 Raktim K Ghosh4 1Department of Internal Medicine, University of Connecticut, Hartford, CT, USA; 2Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA; 3Department of ...
Gupta M, Rao S, Manek G, Fonarow GC, Ghosh RK   +4 more
doaj  

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding

Cells, 2020
Heart failure (HF) is the most rapidly growing cardiovascular health burden worldwide. HF can be classified into three groups based on the percentage of the ejection fraction (EF): heart failure with reduced EF (HFrEF), heart failure with mid-range—
Steven J. Simmonds, Ilona Cuijpers, Stephane Heymans, Elizabeth A. V. Jones   +3 more
doaj   +1 more source

Risk factors for new-onset heart failure with reduced or preserved ejection fraction in patients with ischemic heart disease: A cohort study

Journal of Clinical Sciences, 2021
Background: Risk factors for heart failure (HF) with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF) in Ethiopian and Sub-Saharan African patients with ischemic heart disease (IHD) is not well-known.
Senbeta Guteta Abdissa
doaj   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model

Health Technology Assessment, 2017
Background: Heart failure (HF) affects around 500,000 people in the UK. HF medications are frequently underprescribed and B-type natriuretic peptide (BNP)-guided therapy may help to optimise treatment.
Maria Pufulete, Rachel Maishman, Lucy Dabner, Syed Mohiuddin, William Hollingworth, Chris A Rogers, Julian Higgins, Mark Dayer, John Macleod, Sarah Purdy, Theresa McDonagh, Angus Nightingale, Rachael Williams, Barnaby C Reeves   +13 more
doaj   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources